recombinant human chorionic gonadotropin

ApprovedBiologic

recombinant human chorionic gonadotropin is one of 78 biologic programs targeting Hypogonadotropic Hypogonadism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypogonadotropic HypogonadismActive, not recruiting

Polycystic Ovary SyndromeActive, not recruiting

Breast CancerActive, not recruiting

Hypogonadotropic HypogonadismApproved

Active, not recruiting

Polycystic Ovary SyndromePhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

recombinant human chorionic gonadotropin

Merck & Co.

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polycystic Ovary Syndrome3 trials

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

Completed·UUniversity of California, San Diego·Phase 3·NCT00747617·25 enrolled

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

Completed·UUniversity of California, San Diego·N/A·NCT00989781·41 enrolled

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

Completed·UUniversity of California, San Diego·Phase 3·NCT01154192·24 enrolled

Ovarian Stimulation2 trials

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

Completed·RRegionshospitalet Viborg, Skive·Phase 4·NCT01339299·100 enrolled

A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01497197·174 enrolled

Breast Cancer1 trial

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Terminated·FFox Chase Cancer Center·N/A·NCT00700778·2 enrolled

Assisted Reproductive Technology1 trial

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00505752·520 enrolled

Ovulation Induction1 trial

AS900672-Enriched in Ovulation Induction

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00553514·71 enrolled

3 more indications

Treatment1 trial

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01297465·202 enrolled

Hypogonadotropic Hypogonadism1 trial

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Terminated· EMD Serono logo

EMD Serono·Phase 4·NCT00328926·11 enrolled

Controlled Ovarian Stimulation1 trial

A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation

Completed· Ferring logo

Ferring·Phase 3·NCT02449889·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for recombinant human chorionic gonadotropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant human chorionic gonadotropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant human chorionic gonadotropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Merck & Co.

recombinant human chorionic gonadotropin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polycystic Ovary Syndrome3 trials

Ovarian Stimulation2 trials

Breast Cancer1 trial

Assisted Reproductive Technology1 trial

Ovulation Induction1 trial

Treatment1 trial

Hypogonadotropic Hypogonadism1 trial

Controlled Ovarian Stimulation1 trial

References

Drug Info

Quick Facts

Related News